RI
AXSM icon

RTW Investments’s Axsome Therapeutics AXSM Stock Holding History

RTW Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-888,001
Closed -$162M – 90
2025
Q4 		$162M Sell
888,001
-230,882
-21% -$32.2M 1.62% 20
2025
Q3 		$136M Sell
1,118,883
-398,020
-26% -$44.8M 1.67% 19
2025
Q2 		$158M Sell
1,516,903
-1,405,826
-48% -$149M 2.26% 15
2025
Q1 		$341M Sell
2,922,729
-1,128,636
-28% -$129M 5.21% 5
2024
Q4 		$343M Sell
4,051,365
-138,192
-3% -$12.7M 5.18% 4
2024
Q3 		$377M Sell
4,189,557
-444,774
-10% -$38.8M 5.45% 2
2024
Q2 		$373M Buy
4,634,331
+141,652
+3% +$10.5M 5.78% 3
2024
Q1 		$359M Buy
4,492,679
+3,083
+0.1% +$259K 5.29% 3
2023
Q4 		$357M Hold
4,489,596
– – 5.58% 4
2023
Q3 		$314M Buy
4,489,596
+205,319
+5% +$15.3M 6.62% 3
2023
Q2 		$308M Buy
4,284,277
+503,422
+13% +$37.1M 5.86% 4
2023
Q1 		$233M Buy
3,780,855
+800,373
+27% +$52.6M 4.86% 7
2022
Q4 		$230M Buy
2,980,482
+1,098,318
+58% +$65.6M 4.69% 6
2022
Q3 		$84M Buy
1,882,164
+263,345
+16% +$13.2M 1.94% 19
2022
Q2 		$62M Hold
1,618,819
– – 1.6% 23
2022
Q1 		$67M Hold
1,618,819
– – 1.39% 28
2021
Q4 		$61.2M Buy
1,618,819
+2,322
+0.1% +$85.4K 0.89% 33
2021
Q3 		$53.3M Hold
1,616,497
– – 0.8% 36
2021
Q2 		$109M Hold
1,616,497
– – 1.65% 22
2021
Q1 		$91.5M Sell
1,616,497
-55,919
-3% -$3.93M 1.43% 24
2020
Q4 		$136M Buy
1,672,416
+1,478
+0.1% +$111K 2.29% 11
2020
Q3 		$119M Buy
1,670,938
+12,622
+0.8% +$984K 2.87% 9
2020
Q2 		$136M Buy
1,658,316
+605,347
+57% +$46.6M 3.84% 7
2020
Q1 		$61.9M Buy
1,052,969
+26,156
+3% +$2.13M 2.67% 13
2019
Q4 		$106M Buy
1,026,813
+180,692
+21% +$7.3M 4% 5
2019
Q3 		$17.1M Buy
846,121
+1,832
+0.2% +$47.1K 1.02% 27
2019
Q2 		$21.7M Buy
844,289
+248,654
+42% +$4.98M 1.16% 25
2019
Q1 		$8.48M Buy
+595,635
New +$5.53M 0.58% 35

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments's AXSM Position: Q1 2026 in Review

RTW Investments sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 888,001 shares — an estimated $162M sold.

RTW Investments first reported a position in AXSM in Q1 2019 and held it in 28 quarters. The position peaked at $377M in Q3 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • RTW Investments reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • RTW Investments sold 888,001 Axsome Therapeutics shares in Q1 2026, an estimated $162M.
  • RTW Investments first reported a position in Axsome Therapeutics in Q1 2019 and held it in 28 quarters.
  • RTW Investments's Axsome Therapeutics position peaked at $377M in Q3 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.